Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery

Kishor M. Wasan; Dion R. Brocks; Stephen D. Lee; Kristina Sachs-Barrable; Sheila J. Thornton

doi:10.1038/nrd2353

journal article Jan 01, 2008

Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery

Kishor M. Wasan Dion R. Brocks Stephen D. Lee Kristina Sachs-Barrable Sheila J. Thornton

Nature Reviews Drug Discovery Vol. 7 No. 1 pp. 84-99 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/nrd2353

Topics

No keywords indexed for this article. Browse by subject →

References

192

[1]

Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs

Christopher J. H. Porter, Natalie L. Trevaskis, William N. Charman

Nature Reviews Drug Discovery 2007 10.1038/nrd2197

[2]

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 106, 3143–3421 (2002). 10.1161/circ.106.25.3143

[3]

Saari, K. M. et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J. Clin. Psychiatry 66, 559–563 (2005). 10.4088/jcp.v66n0503

[4]

Newcomer, J. W. Medical risk in patients with bipolar disorder and schizophrenia. J. Clin. Psychiatry 67, e16 (2006). 10.4088/jcp.1106e16

[5]

Furberg, A. S., Veierod, M. B., Wilsgaard, T., Bernstein, L. & Thune, I. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J. Natl. Cancer Inst. 96, 1152–1160 (2004). 10.1093/jnci/djh216

[6]

Wuermli, L. et al. Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer. Prostatic Dis. 8, 316–320 (2005). 10.1038/sj.pcan.4500834

[7]

Herbey, I. I., Ivankova, N. V., Katkoori, V. R. & Mamaeva, O. A. Colorectal cancer and hypercholesterolemia: review of current research. Exp. Oncol. 27, 166–178 (2005).

[8]

Fiorenza, A. M., Branchi, A. & Sommariva, D. Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int. J. Clin. Lab. Res. 30, 141–145 (2000). 10.1007/s005990070013

[9]

Vitols, S., Gahrton, G., Bjorkholm, M. & Peterson, C. Hypocholesterolaemia in malignancy due to elevated low-density-lipoprotein-receptor activity in tumour cells: evidence from studies in patients with leukaemia. Lancet 2, 1150–1154 (1985). 10.1016/s0140-6736(85)92679-0

[10]

Vitols, S. et al. Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy. Proc. Natl Acad. Sci. USA 87, 2598–2602 (1990). 10.1073/pnas.87.7.2598

[11]

Pajukanta, P. et al. Genomewide scan for familial combined hyperlipidemia genes in finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B levels. Am. J. Hum. Genet. 64, 1453–1463 (1999). 10.1086/302365

[12]

Garg, A. & Simha, V. Update on dyslipidemia. J. Clin. Endocrinol. Metab. 92, 1581–1589 (2007). 10.1210/jc.2007-0275

[13]

Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral‐naïve cohort

WM El‐Sadr, CM Mullin, A Carr et al.

HIV Medicine 2005 10.1111/j.1468-1293.2005.00273.x

[14]

Feingold, K. R. et al. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J. Clin. Endocrinol. Metab. 76, 1423–1427 (1993).

[15]

Grunfeld, C. et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 74, 1045–1052 (1992).

[16]

Vernes, A. et al. Changes of serum lipoproteins during the course of human malaria (author's transl). Pathol. Biol. (Paris) 28, 457–460 (1980).

[17]

Nilsson-Ehle, I. & Nilsson-Ehle, P. Changes in plasma lipoproteins in acute malaria. J. Intern. Med. 227, 151–155 (1990). 10.1111/j.1365-2796.1990.tb00136.x

[18]

Mohanty, S. et al. Altered plasma lipid pattern in falciparum malaria. Ann. Trop. Med. Parasitol. 86, 601–606 (1992). 10.1080/00034983.1992.11812715

[19]

Maurois, P., Pessah, M., Briche, I. & Alcindor, L. G. Alterations of lecithin-cholesterol acyltransferase activity during Plasmodium chabaudi rodent malaria. Biochimie 67, 227–239 (1985). 10.1016/s0300-9084(85)80051-1

[20]

Parola, P. et al. Hypertriglyceridemia as an indicator of the severity of falciparum malaria in returned travelers: a clinical retrospective study. Parasitol. Res. 92, 464–466 (2004). 10.1007/s00436-003-1012-5

[21]

Brocks, D. R. & Wasan, K. M. The influence of lipids on stereoselective pharmacokinetics of halofantrine: Important implications in food-effect studies involving drugs that bind to lipoproteins. J. Pharm. Sci. 91, 1817–1826 (2002). 10.1002/jps.10182

[22]

Humberstone, A. J., Porter, C. J. & Charman, W. N. A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. J. Pharm. Sci. 85, 525–529 (1996). 10.1021/js950472p

[23]

Humberstone, A. J., Porter, C. J., Edwards, G. A. & Charman, W. N. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state. J. Pharm. Sci. 87, 936–942 (1998). With co-administration of a high-fat meal, halofantrine absorption increases due to enhanced solubility of the drug in the intestinal tract. However, the authors noted that the clearance of the drug also decreases in such a state, thus contributing to increased plasma concentrations after oral dosing in the presence of a high-fat meal. This has important implications in interpreting food-effect studies of drugs that bind to lipoproteins. 10.1021/js9704846

[24]

Mathis, A. S., Dave, N., Knipp, G. T. & Friedman, G. S. Drug-related dyslipidemia after renal transplantation. Am. J. Health. Syst. Pharm. 61, 565–585; quiz 586–587 (2004). 10.1093/ajhp/61.6.565

[25]

Lopez, M. M. et al. Long-term problems related to immunosuppression. Transpl. Immunol. 17, 31–35 (2006). 10.1016/j.trim.2006.09.018

[26]

Hughes, F. N. Compendium of Pharmaceuticals and Specialties. CPS 35 (2000).

[27]

Wirshing, D. A. Schizophrenia and obesity: impact of antipsychotic medications. J. Clin. Psychiatry 65, Suppl 18, 13–26 (2004).

[28]

Wirshing, D. A. et al. Novel antipsychotics: comparison of weight gain liabilities. J. Clin. Psychiatry 60, 358–363 (1999). 10.4088/jcp.v60n0602

[29]

Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes

Diabetes Care 10.2337/diacare.27.2.596

[30]

Montessori, V., Press, N., Harris, M., Akagi, L. & Montaner, J. S. Adverse effects of antiretroviral therapy for HIV infection. CMAJ 170, 229–238 (2004).

[31]

Mallon, P. W. Pathogenesis of lipodystrophy and lipid abnormalities in patients taking antiretroviral therapy. AIDS Rev. 9, 3–15 (2007).

[32]

Shayeganpour, A., Jun, A. S. & Brocks, D. R. Pharmacokinetics of Amiodarone in hyperlipidemic and simulated high fat-meal rat models. Biopharm. Drug Dispos. 26, 249–257 (2005). 10.1002/bdd.457

[33]

Aliabadi, H. M., Spencer, T. J., Mahdipoor, P., Lavasanifar, A. & Brocks, D. R. Insights into the effects of hyperlipoproteinemia on cyclosporine A biodistribution and relationship to renal function. AAPS J. 8, E672–81 (2006). 10.1208/aapsj080477

[34]

Vadiei, K., Lopez-Berestein, G. & Luke, D. R. Disposition and toxicity of amphotericin-B in the hyperlipidemic Zucker rat model. Int. J. Obes. 14, 465–472 (1990).

[35]

Nakamura, T. et al. Effect of serum triglyceride concentration on the fluctuation of whole blood concentration of cyclosporin A in patients. Biol. Pharm. Bull. 24, 683–687 (2001). 10.1248/bpb.24.683

[36]

Gupta, S. K. & Benet, L. Z. High-fat meals increase the clearance of cyclosporine. Pharm. Res. 7, 46–48 (1990). This paper showed that increased lipoprotein concentrations increased drug clearance and volume of distribution. 10.1023/a:1015831408425

[37]

Kim, M. S. et al. Differences in the pharmacokinetics of peroxisome proliferator-activated receptor agonists in genetically obese Zucker and sprague-dawley rats: implications of decreased glucuronidation in obese Zucker rats. Drug Metab. Dispos. 32, 909–914 (2004). 10.1016/s0090-9556(24)02972-6

[38]

Gupta, S. K. et al. Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. J. Clin. Pharmacol. 30, 643–653 (1990). 10.1002/j.1552-4604.1990.tb01868.x

[39]

Tan, K. K. et al. Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients. Clin. Pharmacol. Ther. 57, 425–433 (1995). 10.1016/0009-9236(95)90212-0

[40]

Brocks, D. R., Ala, S. & Aliabadi, H. M. The effect of increased lipoprotein levels on the pharmacokinetics of cyclosporine A in the laboratory rat. Biopharm. Drug Dispos. 27, 7–16 (2006). 10.1002/bdd.476

[41]

Chao, Y. S., Windler, E. E., Chen, G. C. & Havel, R. J. Hepatic catabolism of rat and human lipoproteins in rats treated with 17 alpha-ethinyl estradiol. J. Biol. Chem. 254, 11360–11366 (1979). 10.1016/s0021-9258(19)86494-3

[42]

Brunner, L. J., Vadiei, K. & Luke, D. R. Cyclosporine disposition in the hyperlipidemic rat model. Res. Commun. Chem. Pathol. Pharmacol. 59, 339–348 (1988).

[43]

Shah, A. K. & Sawchuk, R. J. Effect of co-administration of intralipid on the pharmacokinetics of cyclosporine in the rabbit. Biopharm. Drug Dispos. 12, 457–466 (1991). 10.1002/bdd.2510120607

[44]

Wasan, K. M., Grossie, V. B. Jr & Lopez-Berestein, G. Concentrations in serum and distribution in tissue of free and liposomal amphotericin B in rats during continuous intralipid infusion. Antimicrob. Agents Chemother. 38, 2224–2226 (1994). 10.1128/aac.38.9.2224

[45]

Eliot, L. A., Foster, R. T. & Jamali, F. Effects of hyperlipidemia on the pharmacokinetics of nifedipine in the rat. Pharm. Res. 16, 309–313 (1999). 10.1023/a:1018896912889

[46]

Milton, K. A., Edwards, G., Ward, S. A., Orme, M. L. & Breckenridge, A. M. Pharmacokinetics of halofantrine in man: effects of food and dose size. Br. J. Clin. Pharmacol. 28, 71–77 (1989). 10.1111/j.1365-2125.1989.tb03507.x

[47]

Santos, P. et al. Parenteral nutrition and cyclosporine: do lipids make a difference? A prospective randomized crossover trial. Clin. Nutr. 20, 31–36 (2001). 10.1054/clnu.2000.0151

[48]

Vincon, G., Ploux, D., Pehourcq, F. & Albin, H. Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits. J. Pharmacol. 14, 47–55 (1983).

[49]

Wojcicki, J. et al. Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects. Biopharm. Drug Dispos. 24, 211–218 (2003). 10.1002/bdd.357

[50]

Wojcicki, J. et al. Studies on the pharmacokinetics and pharmacodynamics of propranolol in hyperlipidemia. J. Clin. Pharmacol. 39, 826–833 (1999). 10.1177/00912709922008498

Showing 50 of 192 references

Cited By

216

Lipophilicity and biomimetic properties measured by HPLC to support drug discovery

Klára L. Valkó · 2016

Journal of Pharmaceutical and Biome...

Metrics

216

Citations

192

References

Details

Published: Jan 01, 2008
Vol/Issue: 7(1)
Pages: 84-99
License: View

Authors

Kristina Sachs-Barrable

S

Sheila J. Thornton

Cite This Article

Kishor M. Wasan, Dion R. Brocks, Stephen D. Lee, et al. (2008). Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nature Reviews Drug Discovery, 7(1), 84-99. https://doi.org/10.1038/nrd2353

Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery

You May Also Like